What does it take to drive innovation in Japan? What is the necessary biotech ecosystem to make it successful? Is Japan's science among the best in the world?
Please join us to hear Dr. Toshio Fujimoto's passionate leadership journey to shape iPark, the first pharma-led open-innovation health ecosystem in Japan, founded in April 2018. Now in its fifth year, this ecosystem--built on pharmaceutical know-how and collaboration among industry, government, and academia--brings together expertise to incubate and accelerate the translation of cutting-edge science into impactful health solutions for patients in Japan and around the world.
Networking is an important part of innovation culture and, in this community, companies inspire one another to come up with disruptive ideas and make it a part of daily business. More than 2,200 residents from about 150 pharmaceutical, next-generation-medicine, artificial-intelligence, venture-capital, and government-related companies and organizations are part of iPark.
日時：2022年7月15日（金）17:00-18:00 (presentation); 18:00-18:30 (networking)
This is a Japanese-language event. Japanese-English simultaneous interpretation will be provided by KUDO during the presentation portion. This event will be hosted as a webinar. Instructions for joining the virtual meeting will be sent to registered attendees after the above-stated deadline.
Date: Friday, July 15, 2022
Time: 17:00-18:00 (presentation); 18:00-18:30 (networking)
Speaker: Dr. Toshio Fujimoto, general manager of Shonan Health Innovation Park (iPark) and head of global public affairs at Takeda Pharmaceutical
Moderators: Takehiro Aoki of Eli Lilly and Mie Kitano of Synfiny Advisors and co-chair of the Kansai Business Programs and Diversity and Inclusion Committees
About the Speaker
藤本利夫氏は湘南ヘルスイノベーションパーク (湘南アイパーク)のジェネラルマネジャー・武田薬品工業グローバルパブリックアフェアーズ ヘッドを勤めています。湘南アイパークでの活動を見守り、戦略的なリーダーシップを発揮しています。また、世界に開かれたライフサイエンスエコシステムを構築し、革新的なアイデアを社会実装する場を目指す湘南アイパークのビジョンを実現しています。武田薬品工業グローバルパブリックアフェアーズではイノベーションに繋がり、医療への平等なアクセスを可能にする政策形成活動をリードしています。
Toshio Fujimoto MD, MBA, is general manager of Shonan Health Innovation Park (iPark) and head of global public affairs at Takeda Pharmaceutical. He took on his current role at iPark in 2017 and provides strategic leadership and oversight for all key iPark activities. Fujimoto implements iPark's vision to be an open innovation ecosystem which builds meaningful collaborations with academia, biotech, pharma companies, and the government. In his global public affairs role, he leads activities that shape policies for innovation and its equitable access for patients.
Fujimoto received his doctor of medicine degree from Kyoto University and his MBA from Kobe University. He began his clinical practice as a resident at the Department of Thoracic Surgery at Kyoto University Hospital. After completing several rotations at local area hospitals, he took a position in Germany as an assistant surgeon with the Thoracic Surgery Department at Ruhrlandklinik Hospital, and later moved to the United States to serve as clinical fellow of general thoracic surgery at the Mayo Clinic.
Prior to joining Shonan iPark, Fujimoto held positions with increasing responsibility at Eli Lilly Japan. Most recently, he was vice president of the Medicines Development Unit, where he oversaw management of research and development in Japan.
*This event is supported by LINK-J (Life Science Innovation Network Japan).
ACCJ-Kansai Business Programs Committee: Mie Kitano and Yasumasa Sakamoto, co-chairs
NOTE 1: This event is OFF THE RECORD.
NOTE 2: Please note that, as with all guest presentations, the content and comments of the speakers reflect their own opinions and do not necessarily represent the opinions or policies of the ACCJ.
NOTE 3: If you cancel after the stated deadline, the full meeting fee will be charged to your account.
ACCJ Member Fee: ¥0, Guest Fee: ¥0
ACCJ Kansai Chapter email@example.com